SUO 2019: Active Surveillance versus Office Fulguration or Laser Treatment
SUO 2019 management of small, low grade bladder cancer recurrences, risk-adapted management approach for patients with low-grade Ta bladder tumors.
Related Articles
Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer – Marco Moschini
Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer. Dr. Moschini presents his single-center retrospective study from San…
Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish – Beyond the Abstract
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
Optimizing Treatment in Metastatic Hormone-Sensitive Prostate Cancer: A Case Study Analysis – Alicia Morgans
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…
Landscape of Approved and Upcoming PSMA Imaging Agents “Presentation” – Amir Iravani
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…
Mentoring the Next Generation of GU Oncology Leaders – Andrea Apolo
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting…
Mentoring the Next Generation of GU Oncology Leaders – Andrea Apolo
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting…
The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer – Matthew Abramowitz
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
Real-World Evidence Informs Clinical Decision-Making in Metastatic Castration-Resistant Prostate Cancer – Alan Bryce
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alan…
Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management – Oliver Sartor
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: A.…
ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions – Nimira Alimohamed
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…